Literature DB >> 18446509

Prodrug approaches for CNS delivery.

Jarkko Rautio1, Krista Laine, Mikko Gynther, Jouko Savolainen.   

Abstract

Central nervous system (CNS) drug delivery remains a major challenge, despite extensive efforts that have been made to develop novel strategies to overcome obstacles. Prodrugs are bioreversible derivatives of drug molecules that must undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which subsequently exerts the desired pharmacological effect. In both drug discovery and drug development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents that overcome barriers to a drug's usefulness. This review provides insight into various prodrug strategies explored to date for CNS drug delivery, including lipophilic prodrugs, carrier- and receptor-mediated prodrug delivery systems, and gene-directed enzyme prodrug therapy.

Mesh:

Substances:

Year:  2008        PMID: 18446509      PMCID: PMC2751454          DOI: 10.1208/s12248-008-9009-8

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  89 in total

1.  Vector-mediated drug delivery to the brain.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

2.  Why is the global CNS pharmaceutical market so under-penetrated?

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2002-01-01       Impact factor: 7.851

Review 3.  Drug transporters in the central nervous system: brain barriers and brain parenchyma considerations.

Authors:  G Lee; S Dallas; M Hong; R Bendayan
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 25.468

Review 4.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

Review 5.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

Authors:  David J Begley
Journal:  Pharmacol Ther       Date:  2004-10       Impact factor: 12.310

Review 6.  Prodrug strategies to overcome poor water solubility.

Authors:  Valentino J Stella; Kwame W Nti-Addae
Journal:  Adv Drug Deliv Rev       Date:  2007-05-29       Impact factor: 15.470

Review 7.  Prodrug activation enzymes in cancer gene therapy.

Authors:  M Aghi; F Hochberg; X O Breakefield
Journal:  J Gene Med       Date:  2000 May-Jun       Impact factor: 4.565

8.  Systemically administered D-glucose conjugates of 7-chlorokynurenic acid are centrally available and exert anticonvulsant activity in rodents.

Authors:  G Battaglia; M La Russa; V Bruno; L Arenare; R Ippolito; A Copani; F Bonina; F Nicoletti
Journal:  Brain Res       Date:  2000-03-31       Impact factor: 3.252

9.  Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics.

Authors:  T Ooie; T Terasaki; H Suzuki; Y Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  1997-10       Impact factor: 4.030

10.  Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

Authors:  N H Greig; S Genka; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

View more
  33 in total

1.  Commentary: current advances and future directions for CNS delivery.

Authors:  Craig K Svensson; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2008-12-12       Impact factor: 4.009

2.  Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures.

Authors:  Yanping Li; Yangyang Zhou; Jiayu Jiang; Xinyi Wang; Yao Fu; Tao Gong; Xun Sun; Zhirong Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2015-07-08       Impact factor: 6.200

3.  Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications.

Authors:  Zhen Gao; Yang Chen; Xiaoshu Cai; Rong Xu
Journal:  Bioinformatics       Date:  2017-03-15       Impact factor: 6.937

Review 4.  Drug delivery systems, CNS protection, and the blood brain barrier.

Authors:  Ravi Kant Upadhyay
Journal:  Biomed Res Int       Date:  2014-07-20       Impact factor: 3.411

5.  Enhanced brain penetration of hexamethonium in complexes with derivatives of fullerene C60.

Authors:  L B Piotrovskiy; E V Litasova; M A Dumpis; D N Nikolaev; E E Yakovleva; O A Dravolina; A Yu Bespalov
Journal:  Dokl Biochem Biophys       Date:  2016-07-15       Impact factor: 0.788

6.  Targeting Fatty-Acid Amide Hydrolase with Prodrugs for CNS-Selective Therapy.

Authors:  J Matthew Meinig; Skylar J Ferrara; Tania Banerji; Tapasree Banerji; Hannah S Sanford-Crane; Dennis Bourdette; Thomas S Scanlan
Journal:  ACS Chem Neurosci       Date:  2017-08-18       Impact factor: 4.418

7.  Synthesis of a long acting nanoformulated emtricitabine ProTide.

Authors:  Dhruvkumar Soni; Aditya N Bade; Nagsen Gautam; Jonathan Herskovitz; Ibrahim M Ibrahim; Nathan Smith; Melinda S Wojtkiewicz; Bhagya Laxmi Dyavar Shetty; Yazen Alnouti; JoEllyn McMillan; Howard E Gendelman; Benson J Edagwa
Journal:  Biomaterials       Date:  2019-08-20       Impact factor: 12.479

8.  Sobetirome prodrug esters with enhanced blood-brain barrier permeability.

Authors:  Andrew T Placzek; Skylar J Ferrara; Meredith D Hartley; Hannah S Sanford-Crane; J Matthew Meinig; Thomas S Scanlan
Journal:  Bioorg Med Chem       Date:  2016-09-16       Impact factor: 3.641

Review 9.  Which drug or drug delivery system can change clinical practice for brain tumor therapy?

Authors:  Tali Siegal
Journal:  Neuro Oncol       Date:  2013-03-15       Impact factor: 12.300

10.  Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase.

Authors:  Tyler D Baguley; Hai-Chao Xu; Manavi Chatterjee; Angus C Nairn; Paul J Lombroso; Jonathan A Ellman
Journal:  J Med Chem       Date:  2013-10-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.